Targeted pills for advanced adenoid cystic cancer that keeps growing
Part of Cancer clinical trials.
This Phase 2 trial studies targeted “tyrosine kinase inhibitor” pills for adenoid cystic carcinoma that has spread or cannot be cured with surgery or radiation and is growing despite prior treatment. It’s looking for whether these pills can shrink tumors or slow progression and is mainly for adults with measurable disease on recent scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed adenoid cystic carcinoma based on biopsy or cell tests
- Your cancer has grown on a scan between 2 and 12 months before starting the study
- Your cancer cannot be cured with surgery or radiation and has already had prior treatments (like chemotherapy or other local procedures)
- You have at least one measurable tumor spot on scans (so doctors can track response)
- You’re age 18 or older, and your general strength/activity level is 0–3 (ECOG 0–3)
- You have no major organ problems and can follow all study visits and pill schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of high-precision radiation (carbon ions) given to shrink head and neck adenoid cystic carcinoma that cannot be fully removed with surgery. It may help control the tumor while limiting damage to nearby normal tissues.
This Phase 1/2 study tests how well CB-103 works in people with advanced, hard-to-treat adenoid cystic carcinoma that has a specific NOTCH pathway change. The study also looks at whether combining CB-103 with either lenvatinib or abemaciclib is safe and effective for different groups of patients.
This trial tests a new drug called RGT-61159 for adults with adenoid cystic carcinoma or colorectal cancer that has returned or stopped responding to treatment. The goal is to see if the drug is safe and effective in shrinking tumors.
This trial tests a new drug called HG146 for people with advanced adenoid cystic carcinoma that has progressed despite previous treatments. The goal is to see if HG146 can slow or stop the cancer from growing.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
Hear when a new Carcinoma, Adenoid Cystic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.